Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
-$0.10 today
- Market cap
- $99.30M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
Volume 4.42M
Average 17.46M
OTLK Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Outlook Therapeutics, Inc.NASDAQ: OTLK
Accounts Payables · Q2 FY2026 · quarter ended Mar 2026
Accounts payables turns positive
Q2 FY2026 accounts payables was $5.71M, compared with -$4.63M a year earlier. Trailing-twelve-month accounts payables was $4.9M. Over 3 fiscal years it compounded at +8.8% a year.
Context
- Accounts payables amounted to 117.9% of revenue in FY2025.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near $5.71M or moves back toward the trailing-twelve-month quarterly average of $1.23M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 1.67M USD
- Year-over-year change
- +19.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 1.67M | +19.5% |
| FY2024 | 2024-09-30 | 1.39M | -54.8% |
| FY2023 | 2023-09-30 | 3.08M | +138.0% |
| FY2022 | 2022-09-30 | 1.3M | +752.6% |
| FY2021 | 2021-09-30 | (198.47K) | — |
Accounts Payables vs competitors
How OTLK compares with its peers on the latest reported figures
- OTLK's LTM Mar 2026 accounts payables of $4.9M is the 2nd largest of the 9 companies compared; the peer median is $266.74K.
- Its year-over-year change of +28.5% is the 5th highest of 9, against a peer median of +22.8%.
- Accounts payables amounts to 1472.1% of revenue for OTLK, versus a peer median of 5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $12.2M | +1170.0% | +236.9% | — |
| LTM Mar 2026 | $4.9M | +28.5% | +8.8% | 1472.1% | |
| LTM Jun 2026 | $3.45M | -438.7% | +104.0% | 16.4% | |
| LTM Mar 2026 | $1.88M | -646.1% | — | — | |
| LTM Mar 2026 | $764K | +6466.7% | -36.8% | — | |
| LTM Mar 2026 | $458K | +239.3% | +138.4% | 1.4% | |
| LTM Mar 2026 | $424K | -76.4% | — | — | |
| LTM Mar 2026 | $109.49K | -55.4% | +121.5% | 7.7% | |
| LTM Mar 2026 | $64K | +100.9% | — | 2.8% | |
| Peer median (excluding OTLK) | $266.74K | +22.8% | +121.5% | 5.3% | |
Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (53.16M) | (66.05M) | (58.98M) | (75.37M) | (62.42M) |
| Depreciation & Amortization | 262.14K | 204.69K | 44.19K | 113.86K | 117.05K |
| Deferred Income Tax | 498.49K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.89M | 7.71M | 5.55M | 5.39M | 8.9M |
| Change in Working Capital | (7.08M) | (1.68M) | 4.75M | (3.02M) | 4.86M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (1.49M) |
| Inventory | 0 | 0 | 0 | 0 | (3.34M) |
| Accounts Payables | (198.47K) | 1.3M | 3.08M | 1.39M | 1.67M |
| Other Working Capital | (6.88M) | (2.98M) | 1.67M | (4.41M) | 8.02M |
| Other Non-Cash Items | 341.55K | 3.15M | 5.66M | 4.09M | 1.58T |
| Operating Cash Flow | (54.25M) | (56.67M) | (42.97M) | (68.79M) | (51.83M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (3) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 6.31M | (2.32M) | 19.77M | (4.27K) | (3.04M) |
| Common Stock Issued | 46.3M | 62.31M | 30.02M | 60.33M | 48.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.59M | (394.15K) | (823.89K) | 0 | 44.98T |
| Financing Cash Flow | 56.19M | 59.59M | 48.97M | 60.33M | 44.98M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.94M | 2.92M | 6M | (8.46M) | (6.84M) |
| Free Cash Flow | (54.25M) | (56.67M) | (42.97M) | (68.79M) | (51.83M) |
Outlook Therapeutics, Inc.
NASDAQ:OTLK
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.